SynAct Pharma Refines Strategy for Lead Compound Resomelagon

SynAct Pharma AB ( (SE:SYNACT) ) has issued an update.

SynAct Pharma has refined its development strategy for its lead compound, resomelagon, focusing on early intervention in autoimmune diseases such as rheumatoid arthritis and host-directed treatment in viral infections. The company aims to demonstrate the compound’s potential to bring the immune system to a balanced state, creating value for patients and investors. Key initiatives include ongoing recruitment for the ADVANCE Phase 2b study, a Phase 2a study in polymyalgia rheumatica, and the RESOVIR-2 study in dengue. These efforts are supported by promising preclinical and clinical data, positioning SynAct for potential commercial partnerships and expanded applications of resomelagon.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company focused on developing treatments for inflammation through resolution. The company is primarily engaged in advancing its lead compound, resomelagon (AP1189), which offers a novel approach to treating inflammatory diseases, with a particular focus on autoimmune conditions like rheumatoid arthritis and viral infections.

Average Trading Volume: 211,211

Current Market Cap: SEK755.7M

Find detailed analytics on SYNACT stock on TipRanks’ Stock Analysis page.